A Competitive Analysis of the Global Acute Coronary Syndrome (ACS) Therapeutics Market
The ACS therapeutics market is comprised of both branded and generics drugs, the latter of which registers the most revenue.
The market is driven by the ageing population and a prevalence of conditions associated with unhealthy living such as obesity and metabolic disorders such as diabetes.
There are approximately key marketed branded drugs and hundreds of generics indicated for the treatment of ACS. The current treatments increasingly focus on targeting novel orphan pathways for treatment of ACS and to augment the existing class of therapeutics.
These new drug classes are being evaluated to merge various unmet gaps among patients such as statin intolerance, bleeding risks associated with existing blood thinning drugs, and an effective treatment of atherosclerotic plaques.
Among the various classes of ACS therapeutics, anti-hypertensives and cholesterol lowering drugs are currently dominating the ACS therapeutics market with an influx of new drugs targeting novel pathways. The key drug targets include the proprotein convertase subtilisin/kexin type 9 (PCSK9) and cholesteryl ester transfer protein (CETP).
The next 5 years are expected to witness the launch of the key drugs Losmapimod (GSK), Praluent (Sanofi & Regeneron), Anacetrapib (Merck & Co.), Evacetrapib (Eli Lilly and Co.), and Evolocumab (Amgen), which will boost market share for branded drugs to approximately %.
oLosmapimod from GSK’s drug portfolio is an anti-inflammatory drug which inhibits the p38 mitogen activated protein kinase (MAPK) and is being evaluated in Phase clinical trials (LATITUDE-TIMI 60).
About this report
This research service offers an assessment for marketed and pipeline products for the global ACS therapeutics market. Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology. The marketed and pipeline products are broadly segmented into anti-platelet therapeutics, anti-hypertensives and cholesterol lowering drugs, anti-thrombins, and others. Other upcoming therapies include anti-inflammatories. The forecast period is 2015–2025.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook